MedTrace Logo

Avo In R/R And Previously Untreated MCL

NCT04855695 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-01-21

No results posted yet for this study

Summary

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL).

The names of the study drugs involved in this study are:

* Acalabrutinib
* Venetoclax
* Obinutuzumab

Conditions

Interventions

DRUG

Acalabrutinib

Each study drug is given according to a different schedule: Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol

DRUG

Venetoclax

Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol

DRUG

Obinutuzumab

Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Austin I Kim

    lead OTHER

Principal Investigators

  • Austin I Kim, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-02
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855695 on ClinicalTrials.gov